BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aratana Therapeutics Appoints Craig Tooman to Board of Directors


5/9/2012 12:15:45 PM

KANSAS CITY, Kan. and NEW YORK, May 9, 2012 /PRNewswire/ -- Aratana Therapeutics, an animal health company developing innovative medicines for companion animals, has announced the appointment of Craig Tooman, to its Board of Directors.

During his distinguished career, Mr. Tooman has held various senior positions in the pharmaceutical industry in international finance, sales, market research, business intelligence, strategic business management, and investor relations. After nearly a decade with Pharmacia & Upjohn (now Pfizer), Mr. Tooman moved to the biotechnology industry.

Mr. Tooman has made substantial contributions to companies including Ilex Oncology, which was sold to Genzyme Corporation for $1.1 billion; Enzon Pharmaceuticals and Ikaria. Mr. Tooman has recently been appointed CEO of Avanzar Medical, and he has been named entrepreneur-in-residence by the Cancer Prevention and Research Institute of Texas.

"Craig's exceptional track record guiding the evolution of different types of life sciences companies, his experience not just with finance but with all the disciplines that create a company's growth potential, and his ability to communicate with the financial community are skills Aratana will draw on extensively as we continue to develop new medicines to address unmet needs in companion animal health," says Board of Directors Chair Dr. Steven St. Peter.

Mr. Tooman has a Bachelor of Arts degree in economics with a minor in Japanese Language and a concentration in International Finance from Kalamazoo College. He received his MBA in Finance from the University of Chicago.

"Aratana's business model is unique and compelling in the animal health industry, and I believe the team guiding the company is exceptional," Mr. Tooman says. "I look forward to serving on the Board of Directors and helping shape the future of this very exciting enterprise."

About Aratana Therapeutics

Aratana Therapeutics is an animal health drug development company uniquely positioned to deliver high quality new medicines for unmet needs in animal health. Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then out-licenses to or partners with major animal health companies for commercialization. For more information, please visit www.aratanatherapeutics.com.

Contact: Dr. Linda Rhodes, CEO (lrhodes@aratanarx.com), 732-895-5420

SOURCE Aratana Therapeutics



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES